Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ritva Peltomaa

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Frontiers in Immunology|October 11, 2021
Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis <i>In Vivo</i> and Baseline Signaling Profile Associates With Treatment ResponseMaaria Palmroth, Krista Kuuliala, Ritva Peltomaa, et al.
Clinical and Experimental Immunology|September 20, 2022
Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment responseAtte Valli, Krista Kuuliala, Anniina Virtanen, et al.
Magma (New York, N.Y.)|April 15, 2026
CMR T1 and T2 mapping and extracellular volume quantification in systolic phase produces superior image quality with less motion artifacts and equal mapping values compared to conventional diastolic mappingJohanna Federico, Suvi Syväranta, Miia Holmström, et al.
Rheumatology (Oxford, England)|February 15, 2021
Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviewsAnna-Maria Hoffmann-Vold, Elisabeth Bendstrup, Theodoros Dimitroulas, et al.
Annals of the Rheumatic Diseases|March 23, 2022
Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countriesBenedicte Delcoigne, Lotta Ljung, Sella A Provan, et al.
Annals of the Rheumatic Diseases|August 3, 2013
Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trialVappu Rantalaiho, Hannu Kautiainen, Markku Korpela, et al.
Seminars in Arthritis and Rheumatism|March 14, 2013
Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based studyKalle J Aaltonen, Liisa M Virkki, Esa Jämsen, et al.
The Journal of Rheumatology|March 2, 2021
Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid ArthritisKaterina Chatzidionysiou, Merete Lund Hetland, Thomas Frisell, et al.
Science Advances|April 30, 2025
Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypesEmil Hiitola, Juuso Korhonen, Heidi Kokkonen, et al.
RMD Open|February 20, 2025
Challenge of missing data in observational studies: investigating cross-sectional imputation methods for assessing disease activity in axial spondyloarthritisStylianos Georgiadis, Marion Pons, Simon Rasmussen, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Frontiers in Immunology|October 11, 2021
Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis <i>In Vivo</i> and Baseline Signaling Profile Associates With Treatment ResponseMaaria Palmroth, Krista Kuuliala, Ritva Peltomaa, et al.
Clinical and Experimental Immunology|September 20, 2022
Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment responseAtte Valli, Krista Kuuliala, Anniina Virtanen, et al.
Magma (New York, N.Y.)|April 15, 2026
CMR T1 and T2 mapping and extracellular volume quantification in systolic phase produces superior image quality with less motion artifacts and equal mapping values compared to conventional diastolic mappingJohanna Federico, Suvi Syväranta, Miia Holmström, et al.
Rheumatology (Oxford, England)|February 15, 2021
Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviewsAnna-Maria Hoffmann-Vold, Elisabeth Bendstrup, Theodoros Dimitroulas, et al.
Annals of the Rheumatic Diseases|March 23, 2022
Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countriesBenedicte Delcoigne, Lotta Ljung, Sella A Provan, et al.
Annals of the Rheumatic Diseases|August 3, 2013
Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trialVappu Rantalaiho, Hannu Kautiainen, Markku Korpela, et al.
Seminars in Arthritis and Rheumatism|March 14, 2013
Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based studyKalle J Aaltonen, Liisa M Virkki, Esa Jämsen, et al.
The Journal of Rheumatology|March 2, 2021
Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid ArthritisKaterina Chatzidionysiou, Merete Lund Hetland, Thomas Frisell, et al.
Science Advances|April 30, 2025
Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypesEmil Hiitola, Juuso Korhonen, Heidi Kokkonen, et al.
RMD Open|February 20, 2025
Challenge of missing data in observational studies: investigating cross-sectional imputation methods for assessing disease activity in axial spondyloarthritisStylianos Georgiadis, Marion Pons, Simon Rasmussen, et al.
Pageof 3